AstraZeneca & ZS Pharma v. Lupin: LOKELMA Patent Dispute Ends in Consent Judgment
ZS Pharma and AstraZeneca filed suit against Lupin in Delaware asserting 13 patents protecting LOKELMA (sodium zirconium cyclosilicate), a leading treatment for hyperkalaemia. After 1,043 days of litigation, the parties reached a negotiated settlement memorialised in a consent judgment and injunction entered by the court.
A 13-patent ANDA fortress around LOKELMA ends in negotiated peace
Filed on 10 August 2022 in the District of Delaware before Judge Jennifer L. Hall, this Hatch-Waxman action saw ZS Pharma, Inc. and AstraZeneca Pharmaceuticals LP assert 13 US patents against Lupin Limited and Lupin Pharmaceuticals, Inc. The patents collectively cover the composition, formulation, and therapeutic use of sodium zirconium cyclosilicate — the active ingredient in LOKELMA, a selective potassium binder approved for treating hyperkalaemia in adults.
The case closed on 18 June 2025 via a consent judgment. The parties entered a Settlement Agreement whose commercial terms remain confidential, but the court-entered judgment also includes an injunction against Lupin — a provision that typically signals a negotiated market entry date rather than an immediate finding of non-infringement or invalidity. The consent judgment structure means neither validity nor infringement was adjudicated on the merits.
At 1,043 days, the duration is consistent with fully litigated ANDA cases that reach settlement on the eve of trial or following substantive claim-construction proceedings. The breadth of the patent portfolio — 13 patents spanning composition, formulation, and method-of-use claims — suggests AstraZeneca pursued a layered exclusivity strategy. The specific licence terms and any agreed-upon generic entry date are not disclosed in the public record.
Filing to Consent Judgment in 1043 days
1,043-day duration — nearly 3 years of active ANDA patent litigation in Delaware
Consent judgment entered: what the settlement means for both parties
Consent judgment differs from a litigated win or loss
A consent judgment is a court-entered order reflecting terms the parties themselves negotiated. Unlike a trial verdict, it carries no merits finding on patent validity or infringement. The accompanying injunction entered here is standard in Hatch-Waxman settlements and typically defines when and how a generic may enter the market — it does not necessarily mean Lupin was found to infringe.
No merits adjudicationAstraZeneca retains control of LOKELMA’s exclusivity window
By securing a court-entered injunction as part of the settlement, AstraZeneca and ZS Pharma effectively preserved their ability to define when generic sodium zirconium cyclosilicate enters the US market. The 13-patent portfolio remains intact and unchallenged on the merits, sustaining LOKELMA’s IP moat and limiting Lupin’s commercial options absent an agreed licence date.
Portfolio exclusivity preservedLupin avoids adverse merits ruling but accepts injunctive constraint
Lupin neither secured a finding of invalidity nor a non-infringement ruling — outcomes that would have allowed immediate generic entry. By consenting to the injunction, Lupin accepted a market-entry timeline set by the settlement. This is commercially rational if the agreed entry date aligns with patent expiry or a negotiated licence, but it forecloses early generic launch without AstraZeneca’s consent.
Entry date controlled by settlementLOKELMA’s multi-patent shield raises the bar for future ANDA challengers
With 13 asserted patents and a consent judgment in hand, AstraZeneca signals willingness to litigate extensively and settle on favourable terms. Other ANDA filers targeting LOKELMA must evaluate whether mounting an invalidity campaign against the full patent family is commercially viable. The outcome reinforces the deterrent value of layered pharmaceutical patent portfolios in the potassium binder therapeutic space.
High barrier for next challengerFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ZS Pharma, Inc. | Company | Pharmaceutical IP licensor and branded drug developer — holder of US10398730B2 and 12 further LOKELMA patentsSearch in Eureka ↗ |
| Co-Plaintiff | Astrazeneca Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Defendant | Lupin Limited | Individual | Indian generic pharmaceutical manufacturer and its US subsidiary seeking ANDA approval for sodium zirconium cyclosilicateSearch in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel O’boyle | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gyuhyun (joanne) Bae | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Hassen Sayeed | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Yi Li | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark A. Hayden | Attorney | Counsel for ZS Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing ZS Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Alison M. King | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Ashley Graham | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Kurt A. Mathas | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment records that AstraZeneca and Lupin ‘agreed to terms and conditions representing a negotiated settlement’ and that the parties ‘stipulate and consent to entry of judgment and an injunction.’ This language confirms no contested merits ruling was issued — validity and infringement questions remain legally unresolved. The inclusion of an injunction, however, is significant: it gives AstraZeneca an enforceable court order governing Lupin’s market conduct, making the settlement operationally equivalent to a win on exclusivity without the uncertainty of trial.
US10398730B2 and 12 further patents — sodium zirconium cyclosilicate formulations
The 13 asserted patents span multiple layers of protection for sodium zirconium cyclosilicate (SZC), the active ingredient in LOKELMA. The portfolio covers crystalline composition claims, oral suspension formulations (5 g and 10 g packets), manufacturing processes, and methods of treating hyperkalaemia. Application dates range from 2012 through 2018, meaning patent expiry dates are staggered — a deliberate evergreening architecture that extends effective market exclusivity well beyond any single patent’s term.
LOKELMA competes in the selective potassium binder market alongside patiromer (Veltassa). AstraZeneca’s 13-patent fortress reflects the high commercial stakes: LOKELMA generated significant global revenues and faces increasing generic pressure as the ANDA pipeline grows. For competitors, each layer of this portfolio represents a distinct invalidity and non-infringement hurdle. The settlement’s injunction signals that AstraZeneca is prepared to enforce every layer, raising the cost calculus for any subsequent ANDA filer contemplating a Paragraph IV certification.
Should you run an FTO against the LOKELMA sodium zirconium cyclosilicate patent family?
Any company developing, manufacturing, or seeking regulatory approval for generic sodium zirconium cyclosilicate oral suspension products should treat this 13-patent family as a high-priority FTO target. The consent judgment entered against Lupin does not invalidate any claim — all 13 patents remain in force. Product teams commercialising potassium binder formulations in the US market should evaluate composition, formulation, and method-of-use claims independently, as design-around options differ across claim types.
PatSnap Eureka’s FTO Search Agent can map all 13 asserted patents, identify claim-level overlap with your product specifications, flag related continuation and divisional applications not yet asserted, and surface prior art relevant to invalidity arguments. Running a structured FTO before filing an ANDA or NDA is essential given the layered exclusivity architecture AstraZeneca has constructed around sodium zirconium cyclosilicate.
Run a freedom-to-operate analysis on US10398730B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent litigation over potassium binder and nephrology drug formulations
Explore comparable Hatch-Waxman infringement actions in the Delaware District Court involving multi-patent pharmaceutical formulation portfolios in the nephrology and potassium binder space.
What this case signals for the potassium binder pharmaceutical IP landscape
A 13-patent consent judgment in Delaware sets a clear precedent for how branded pharma defends complex formulation-based drug portfolios.
Layered patent portfolios create durable Hatch-Waxman leverage
AstraZeneca’s assertion of 13 patents across composition, formulation, and method-of-use claims illustrates how pharmaceutical companies construct overlapping exclusivity layers. Each additional patent raises the cost and complexity of an ANDA challenge, making early settlement on the brand’s terms more likely. R&D teams developing generic formulations should map the full patent family before filing.
Consent judgments with injunctions are commercially decisive even without a trial
The injunction component of this settlement is as commercially significant as a litigated win for AstraZeneca. Generic manufacturers and their investors should treat consent-judgment injunctions as binding market-entry constraints, not procedural formalities. The absence of a merits ruling means Lupin retains no invalidity finding it could use in future proceedings.
ZS v Lupin — key questions answered
AstraZeneca and ZS Pharma asserted 13 US patents, including US10398730B2, US11406662B2, US9592253B1, US10335432B2, US9861658B2, US10300087B2, US10413569B2, US8877255B2, US10695365B2, US9844567B2, US9913860B2, US8802152B2, and US8808750B2. All cover aspects of sodium zirconium cyclosilicate — the active ingredient in LOKELMA.
The case concerned LOKELMA (sodium zirconium cyclosilicate) for oral suspension, supplied in 5 g and 10 g packets. LOKELMA is a selective potassium binder approved for treating hyperkalaemia in adults. Lupin had filed an ANDA seeking approval to market a generic version, triggering AstraZeneca’s patent infringement action under the Hatch-Waxman framework.
The case closed on 18 June 2025 after 1,043 days via a consent judgment. The parties entered a confidential Settlement Agreement, and the court entered judgment and an injunction against Lupin by stipulation. No merits ruling on patent validity or infringement was issued — the settlement resolved all claims without a trial.
The court-entered injunction constrains Lupin’s ability to commercialise its generic sodium zirconium cyclosilicate product in the US without AstraZeneca’s authorisation. In Hatch-Waxman settlements, such injunctions typically encode a negotiated market-entry date or licence trigger. The specific terms are confidential, but Lupin cannot launch independently while the injunction remains in effect.
No. Because the case resolved by consent judgment rather than a contested trial or IPR, none of the 13 asserted patents were adjudicated invalid or found not infringed. All patents remain in force and enforceable against other ANDA filers. This is a critical distinction for other generic manufacturers evaluating their own Paragraph IV strategies for sodium zirconium cyclosilicate products.
PatSnap Eureka searches patents and litigation data to answer instantly.